Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Change in Accured Expenses: 2022-2025

Historic Change in Accured Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $5.0 million.

  • Taysha Gene Therapies' Change in Accured Expenses rose 1070.09% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 204.99%. This contributed to the annual value of -$1.4 million for FY2024, which is 77.36% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Change in Accured Expenses stood at $5.0 million for Q3 2025, which was up 584.15% from $732,000 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Change in Accured Expenses high stood at $5.0 million for Q3 2025, and its period low was -$7.7 million during Q2 2022.
  • In the last 3 years, Taysha Gene Therapies' Change in Accured Expenses had a median value of -$250,000 in 2023 and averaged -$371,182.
  • Per our database at Business Quant, Taysha Gene Therapies' Change in Accured Expenses tumbled by 2,453.04% in 2023 and then skyrocketed by 1,070.09% in 2025.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Change in Accured Expenses stood at -$747,000 in 2022, then crashed by 170.01% to -$2.0 million in 2023, then spiked by 105.26% to $106,000 in 2024, then soared by 1,070.09% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $732,000 for Q2 2025, and -$2.1 million during Q1 2025.